This site is archived and is no longer updated. It will be taken offline in mid-July. All the latest AWMSG recommendations, guidance and information is available on our new website at:
awmsg logo

pasireotide diaspartate (Signifor®)

Reference No. 642

Publication date:

Appraisal information

pasireotide diaspartate (Signifor®) 0.3 mg solution for injection
pasireotide diaspartate (Signifor®) 0.6 mg solution for injection
pasireotide diaspartate (Signifor®) 0.9 mg solution for injection

Company: Novartis Pharmaceuticals UK Ltd
BNF category: Malignant disease and immunosupression
NMG meeting date: Not scheduled
AWMSG meeting date: Not scheduled
Submission Type: Nonsubmission
Status: Not endorsed
Advice No: Not available
Ratification by Welsh Government: 09/11/2012

Current Progress

Ratification by
Welsh Government

AWMSG advice

In the absence of a submission from the holder of the marketing authorisation, pasireotide (Signifor®) cannot be endorsed for use within NHS Wales for the treatment of adult patients with Cushing’s disease for whom surgery is not an option or for whom surgery has failed.
Statement of Advice (SOA)